These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22241894)

  • 1. The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel?
    Zaritsky JJ; Kalantar-Zadeh K
    J Am Soc Nephrol; 2012 Feb; 23(2):189-91. PubMed ID: 22241894
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.
    Gamboa JL; Pretorius M; Todd-Tzanetos DR; Luther JM; Yu C; Ikizler TA; Brown NJ
    J Am Soc Nephrol; 2012 Feb; 23(2):334-42. PubMed ID: 22158433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.
    Bilić M; Munjas-Samarin R; Ljubanović D; Horvatić I; Galesić K
    Coll Antropol; 2011 Dec; 35(4):1061-6. PubMed ID: 22397239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
    Cohn JN
    Am J Cardiol; 2002 Nov; 90(9):992-3. PubMed ID: 12398968
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
    Rezq A; Saad M; El Nozahi M
    Am J Cardiol; 2021 Mar; 143():7-13. PubMed ID: 33417876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valsartan in acute myocardial infarction trial.
    Piña IL
    Curr Cardiol Rep; 2004 May; 6(3):159-60. PubMed ID: 15075047
    [No Abstract]   [Full Text] [Related]  

  • 7. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Hollenberg NK
    Curr Hypertens Rep; 2002 Dec; 4(6):411; discussion 412. PubMed ID: 12462208
    [No Abstract]   [Full Text] [Related]  

  • 10. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
    Esnault VL; Ekhlas A; Delcroix C; Moutel MG; Nguyen JM
    J Am Soc Nephrol; 2005 Feb; 16(2):474-81. PubMed ID: 15615822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [spACE, the last frontier? Renin inhibition in hypertension].
    Villa L
    G Ital Nefrol; 2008; 25(3):274. PubMed ID: 18473295
    [No Abstract]   [Full Text] [Related]  

  • 12. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
    Lesogor A; Cohn JN; Latini R; Tognoni G; Krum H; Massie B; Zalewski A; Kandra A; Hua TA; Gimpelewicz C
    Eur J Heart Fail; 2013 Nov; 15(11):1236-44. PubMed ID: 23787721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
    Yilmaz MI; Saglam M; Sonmez A; Caglar K; Cakir E; Kurt Y; Eyileten T; Tasar M; Acikel C; Oguz Y; Vural A; Yenicesu M
    Blood Purif; 2007; 25(4):327-35. PubMed ID: 17709915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Maggioni AP; Anand I; Gottlieb SO; Latini R; Tognoni G; Cohn JN;
    J Am Coll Cardiol; 2002 Oct; 40(8):1414-21. PubMed ID: 12392830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VALIANT and EUROPA.
    Liebson PR
    Prev Cardiol; 2004; 7(1):42-4. PubMed ID: 15010627
    [No Abstract]   [Full Text] [Related]  

  • 16. Are angiotensin II receptor blockers indicated in chronic heart failure?
    Komajda M
    Heart; 2002 Jan; 87(1):1-2. PubMed ID: 11751648
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
    Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of valsartan versus enalapril in heart failure patients.
    Willenheimer R; Helmers C; Pantev E; Rydberg E; Löfdahl P; Gordon A;
    Int J Cardiol; 2002 Oct; 85(2-3):261-70. PubMed ID: 12208593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination.
    Trenkwalder P; Schaetzl R; Borbas E; Handrock R; Klebs S
    Blood Press Suppl; 2008 Dec; 2():13-21. PubMed ID: 19205092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.
    Hershon KS
    Endocr Pract; 2011; 17(3):430-40. PubMed ID: 21454245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.